La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
BrightGene Bio-Medical Technology Croissance future
Future contrôle des critères 2/6
BrightGene Bio-Medical Technology is forecast to grow earnings and revenue by 16.8% and 15% per annum respectively. EPS is expected to grow by 16.8% per annum. Return on equity is forecast to be 9.6% in 3 years.
Informations clés
16.8%
Taux de croissance des bénéfices
16.8%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 18.8% |
Taux de croissance des recettes | 15.0% |
Rendement futur des capitaux propres | 9.6% |
Couverture par les analystes | Low |
Dernière mise à jour | 02 Aug 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
Some BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shareholders Look For Exit As Shares Take 29% Pounding
Aug 01BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 47% Share Price Surge Not Quite Adding Up
May 21BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 01Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 1,826 | 309 | 303 | 467 | 2 |
12/31/2025 | 1,538 | 259 | 146 | 390 | 2 |
12/31/2024 | 1,333 | 219 | 36 | 348 | 2 |
3/31/2024 | 1,215 | 196 | -48 | 318 | N/A |
12/31/2023 | 1,180 | 202 | -209 | 195 | N/A |
9/30/2023 | 1,160 | 234 | -185 | 204 | N/A |
6/30/2023 | 1,104 | 237 | -161 | 319 | N/A |
3/31/2023 | 1,074 | 250 | -176 | 366 | N/A |
12/31/2022 | 1,017 | 240 | -415 | 311 | N/A |
9/30/2022 | 1,076 | 265 | -533 | 299 | N/A |
6/30/2022 | 1,074 | 249 | -665 | 207 | N/A |
3/31/2022 | 1,112 | 256 | -821 | 143 | N/A |
12/31/2021 | 1,052 | 244 | -734 | 176 | N/A |
9/30/2021 | 1,023 | 225 | -765 | 149 | N/A |
6/30/2021 | 961 | 203 | -656 | 109 | N/A |
3/31/2021 | 844 | 184 | -439 | 164 | N/A |
12/31/2020 | 785 | 170 | -200 | 155 | N/A |
9/30/2020 | 700 | 169 | -50 | 144 | N/A |
6/30/2020 | 596 | 143 | -32 | 117 | N/A |
3/31/2020 | 544 | 129 | -38 | 70 | N/A |
12/31/2019 | 503 | 111 | -28 | 61 | N/A |
9/30/2019 | 466 | 96 | -20 | 41 | N/A |
6/30/2019 | 445 | 83 | -100 | 52 | N/A |
3/31/2019 | 410 | 74 | -91 | 43 | N/A |
12/31/2018 | 408 | 73 | -48 | 64 | N/A |
12/31/2017 | 317 | 46 | N/A | 36 | N/A |
12/31/2016 | 201 | 17 | N/A | 30 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 688166's forecast earnings growth (16.8% per year) is above the savings rate (2.9%).
Bénéfices vs marché: 688166's earnings (16.8% per year) are forecast to grow slower than the CN market (21.9% per year).
Croissance élevée des bénéfices: 688166's earnings are forecast to grow, but not significantly.
Chiffre d'affaires vs marché: 688166's revenue (15% per year) is forecast to grow faster than the CN market (13.4% per year).
Croissance élevée des revenus: 688166's revenue (15% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 688166's Return on Equity is forecast to be low in 3 years time (9.6%).